A simple blood test may one day tell healthy older adults whether they are likely to develop Alzheimer’s symptoms years before any appear. In a study published in JAMA and presented at the Alzheimer’s Association International Conference in London, researchers found that symptom-free people with very high levels of a protein called p-tau217 had a 38 per cent risk of developing cognitive impairment within five years — a risk that grew to 78 per cent by ten years.
Following Thousands of Healthy Volunteers
The Mass General Brigham team analysed data from 2,684 older adults who were cognitively healthy when they joined long-running Alzheimer’s studies, some as early as 2004. Each received the p-tau217 blood test at enrolment and returned for yearly cognitive check-ups; over the follow-up period, about 478 developed cognitive impairment, allowing the researchers to test how well a single blood result predicted who they would be.
The p-tau217 test measures a form of the tau protein that tracks the build-up of Alzheimer’s plaques and tangles in the brain. It is already used to help diagnose people who arrive at clinics with memory problems. The new question this study asked is different and harder: whether it works as a forecast in people who feel perfectly well.
Promise, With Explicit Cautions
Senior author Dr Reisa Sperling stressed that it is too soon for healthy people to seek out the test, a caution echoed by independent experts. As reporting on the study notes, only a small fraction of participants were followed for the full decade, so the ten-year estimate is less certain than the five-year one, and other causes of decline — including heart-related vascular dementia and competing risks of death in older age — could cloud individual predictions.
In a JAMA commentary, Drs Suzanne Schindler and David Wolk concluded that the tests ‘are not yet precise enough to guide individualised prognosis’. The researchers’ case is narrower and, for now, stronger: the test could identify candidates for prevention trials, and eventually for early treatment, at the stage when intervention is most plausible — much as work on treating hearing loss as a dementia prevention step aims to act on risk long before symptoms arrive.
Why an Early Blood Test Changes the Equation
Alzheimer’s drug development has been transformed by treatments that work best early, yet trials struggle to recruit people who will develop symptoms on a useful timescale. A cheap blood test that enriches that pool could shorten trials and cut their cost dramatically, quite apart from any future clinical use.
For individuals, though, early warning is a double-edged gift: a high-risk result years before symptoms raises questions about insurance, planning and anxiety that medicine is only beginning to work through. The technology of prediction is advancing faster than the ethics and policy around it, and studies like this one are forcing that conversation into the open.
The honest summary is the researchers’ own: this is a powerful research tool and a genuine scientific milestone, but not yet a test healthy people should order. If follow-up work sharpens its precision, the blood draw that predicts Alzheimer’s a decade early may move from conference headline to clinic — and dementia care will be reorganised around it.
